Search
Spotlight
CME Opportunities
CME Opportunities
Specialty
View More
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
News
OncClub
All Oncology News
OncClub
All Oncology News
Media
Insights
MedNews Week
OncChats
OncLive News Network®
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
Insights
MedNews Week
OncChats
OncLive News Network®
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
Conferences
Conference Coverage
Conference Listing
Conference Coverage
Conference Listing
Events
Giants of Cancer Care
CME/CE
Scientific Interchanges
State of the Science Summit / IPC
National Fellows Forum
Webinars
Giants of Cancer Care
CME/CE
Scientific Interchanges
State of the Science Summit / IPC
National Fellows Forum
Webinars
Partners
Publications
Resources
Consensus Viewpoints
OncLive App
Interactive Tools
Sponsored
Consensus Viewpoints
OncLive App
Interactive Tools
Sponsored
Biomarker Consortium
Subscribe
Search
Spotlight
CME Opportunities
Specialty
See All >
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
November 20, 2014 - Episode 4
Pre-Chemo Abiraterone Extends Survival in CRPC
November 21, 2014
EP. 1: Latest News & Insight: November 20, 2014
EP. 2: Upcoming Advances for GU Cancers
EP. 3: ADT With GnRH Antagonists in Prostate Cancer
Now Viewing
EP. 4: Pre-Chemo Abiraterone Extends Survival in CRPC
Related Content:
November 20, 2014
Breast Cancer
Immunotherapy in Melanoma
Melanoma & Skin Cancer
Ovarian Cancer
Brain Cancer
Genitourinary Cancers
Prostate Cancer
FDA Votes Against Risk/Benefit Profile of Talazoparib Plus Enzalutamide for Non-HRR–Mutant mCRPC
Improved Public Awareness and Immunotherapy Drive Down Melanoma Mortality Amid Rising Incidences
Cortice Biosciences Transfers Orphan Drug Designations for TPI 287 in Brain Cancer and CNS Diseases
x